These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34756989)

  • 1. Letter to the Editor for 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study'.
    Harbeck N; Rastogi P; Shahir A; Johnston S; O'Shaughnessy J
    Ann Oncol; 2022 Feb; 33(2):227-228. PubMed ID: 34756989
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Fleming GF; Pagani O; Regan MM; Walley BA; Francis PA
    Ann Oncol; 2022 Jun; 33(6):658. PubMed ID: 35301096
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Harbeck N; Rastogi P; Martin M; Tolaney SM; Shao ZM; Fasching PA; Huang CS; Jaliffe GG; Tryakin A; Goetz MP; Rugo HS; Senkus E; Testa L; Andersson M; Tamura K; Del Mastro L; Steger GG; Kreipe H; Hegg R; Sohn J; Guarneri V; Cortés J; Hamilton E; André V; Wei R; Barriga S; Sherwood S; Forrester T; Munoz M; Shahir A; San Antonio B; Nabinger SC; Toi M; Johnston SRD; O'Shaughnessy J;
    Ann Oncol; 2021 Dec; 32(12):1571-1581. PubMed ID: 34656740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1.
    Toi M; Boyle F; Im YH; Reinisch M; Molthrop D; Jiang Z; Wei R; Sapunar F; Grimes BR; Nabinger SC; Johnston SRD
    Oncologist; 2023 Jan; 28(1):e77-e81. PubMed ID: 36342342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
    Tolaney SM; Guarneri V; Seo JH; Cruz J; Abreu MH; Takahashi M; Barrios C; McIntyre K; Wei R; Munoz M; Antonio BS; Liepa AM; Martin M; Johnston SRD; Kellokumpu-Lehtinen PL; Harbeck N
    Eur J Cancer; 2024 Mar; 199():113555. PubMed ID: 38244363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
    Tarantino P; Burstein HJ; Lin NU; Krop IE; Winer EP; Schnitt SJ; Hamilton EP; Hurvitz SA; Rugo HS; Curigliano G; Tolaney SM
    Ann Oncol; 2022 Mar; 33(3):234-238. PubMed ID: 34942341
    [No Abstract]   [Full Text] [Related]  

  • 7. Abemaciclib Shows Promise for Early Breast Cancer.
    Cancer Discov; 2017 Feb; 7(2):119-120. PubMed ID: 27986713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer.
    Meirson T; Goldstein DA; Gyawali B; Tannock IF
    Lancet Oncol; 2023 Jun; 24(6):589-593. PubMed ID: 37146621
    [No Abstract]   [Full Text] [Related]  

  • 9. Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer - Authors' reply.
    Johnston SRD; Tolaney SM; O'Shaughnessy J; Rastogi P; Harbeck N; Martin M
    Lancet Oncol; 2023 Jun; 24(6):e238. PubMed ID: 37146620
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A.
    Freedman RA; Graff SL; Somerfield MR; Telli ML; Wolff AC; Giordano SH
    JCO Oncol Pract; 2022 Jul; 18(7):516-519. PubMed ID: 35377771
    [No Abstract]   [Full Text] [Related]  

  • 11. In brief: Abemaciclib (Verzenio) for early breast cancer.
    Med Lett Drugs Ther; 2021 Dec; 63(1639):199-200. PubMed ID: 35100237
    [No Abstract]   [Full Text] [Related]  

  • 12. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
    Martin M; Garcia-Saenz JA; Manso L; Llombart A; Cassinello A; Atienza M; Ringeisen F; Ciruelos E
    Future Oncol; 2020 Nov; 16(33):2763-2778. PubMed ID: 32781837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
    Hamilton E; Cortes J; Ozyilkan O; Chen SC; Petrakova K; Manikhas A; Jerusalem G; Hegg R; Huober J; Chapman SC; Lu Y; Hardebeck MC; Bear MM; Johnston EL; Martin M
    Clin Breast Cancer; 2021 Jun; 21(3):181-190.e2. PubMed ID: 33148479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
    Giordano SH; Freedman RA; Somerfield MR;
    J Clin Oncol; 2022 Jan; 40(3):307-309. PubMed ID: 34878801
    [No Abstract]   [Full Text] [Related]  

  • 15. Single-Agent Abemaciclib Active in Breast Cancer.
    Cancer Discov; 2016 Aug; 6(8):809-10. PubMed ID: 27354271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abemaciclib: First Global Approval.
    Kim ES
    Drugs; 2017 Dec; 77(18):2063-2070. PubMed ID: 29128965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
    Seki H; Sakurai T; Sakurada A; Kinoshita T; Shimizu K
    Anticancer Res; 2022 Feb; 42(2):1099-1106. PubMed ID: 35093912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
    Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer].
    Masuda N; Saji S; Kawaguchi T; Chen Y; Ohno S
    Gan To Kagaku Ryoho; 2021 Dec; 48(12):1475-1483. PubMed ID: 34911915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
    Palumbo A; Lau G; Saraceni M
    Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.